Compare Essex Property Trust, Inc. (ESS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Essex Property Trust, Inc. trades at $297.51 (market cap $18.82B), while State Street SPDR S&P Biotech ETF trades at $152.11. The key difference: Essex Property Trust, Inc. pays a 3.54% dividend while State Street SPDR S&P Biotech ETF pays none, and Essex Property Trust, Inc. is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| ESS | XBI | |
|---|---|---|
Market Cap | $18.82B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $298.33 | $164.28 |
52-Week Low | $239.61 | $85.16 |
Enterprise Value | $25.54B | — |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $297.29, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected soon. Fundamentals show robust profitability with a 30.03% net income margin and $669.67M net income for 2025, though valuation ratios like a P/E of 32.93 appear elevated. Recent news highlights sustainability initiatives and inclusion in the Russell Microcap Index.
The outlook for ESS is cautiously optimistic, supported by high West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts are mixed with a $294.25 consensus price target, slightly below the current price, suggesting limited near-term upside amid solid operational performance.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
